1 reports of this reaction
3.2% of all INFLUENZINUM reports
#20 most reported adverse reaction
MEMORY IMPAIRMENT is the #20 most commonly reported adverse reaction for INFLUENZINUM, manufactured by Boiron. There are 1 FDA adverse event reports linking INFLUENZINUM to MEMORY IMPAIRMENT. This represents approximately 3.2% of all 31 adverse event reports for this drug.
Patients taking INFLUENZINUM who experience memory impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MEMORY IMPAIRMENT is moderately reported among INFLUENZINUM users, representing a notable but not dominant share of adverse events.
In addition to memory impairment, the following adverse reactions have been reported for INFLUENZINUM:
The following drugs have also been linked to memory impairment in FDA adverse event reports:
MEMORY IMPAIRMENT has been reported as an adverse event in 1 FDA reports for INFLUENZINUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MEMORY IMPAIRMENT accounts for approximately 3.2% of all adverse event reports for INFLUENZINUM, making it a notable side effect.
If you experience memory impairment while taking INFLUENZINUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.